AU2003299399A1 - Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer - Google Patents
Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancerInfo
- Publication number
- AU2003299399A1 AU2003299399A1 AU2003299399A AU2003299399A AU2003299399A1 AU 2003299399 A1 AU2003299399 A1 AU 2003299399A1 AU 2003299399 A AU2003299399 A AU 2003299399A AU 2003299399 A AU2003299399 A AU 2003299399A AU 2003299399 A1 AU2003299399 A1 AU 2003299399A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- treatment
- specific inhibitor
- 5ht2b receptor
- 5ht2b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 title 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR02/16699 | 2002-12-26 | ||
| FR0216699A FR2849382A1 (en) | 2002-12-26 | 2002-12-26 | USE OF THE HTR2B GENE FOR THE TREATMENT OF PROSTATE CANCER |
| PCT/FR2003/003875 WO2004060390A2 (en) | 2002-12-26 | 2003-12-23 | Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003299399A1 true AU2003299399A1 (en) | 2004-07-29 |
| AU2003299399A8 AU2003299399A8 (en) | 2004-07-29 |
Family
ID=32480198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003299399A Abandoned AU2003299399A1 (en) | 2002-12-26 | 2003-12-23 | Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer |
| AU2003303568A Abandoned AU2003303568A1 (en) | 2002-12-26 | 2003-12-23 | Use of a non-specific inhibitor of the 5ht2b receptor for the treatment of prostate cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003303568A Abandoned AU2003303568A1 (en) | 2002-12-26 | 2003-12-23 | Use of a non-specific inhibitor of the 5ht2b receptor for the treatment of prostate cancer |
Country Status (3)
| Country | Link |
|---|---|
| AU (2) | AU2003299399A1 (en) |
| FR (1) | FR2849382A1 (en) |
| WO (2) | WO2004060390A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592289A (en) * | 2007-04-13 | 2013-03-28 | Southern Res Inst | Anti-Angiogenic Agents and Methods of Use |
| US11034751B1 (en) | 2018-01-30 | 2021-06-15 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using serotonin receptor inhibitors |
| WO2023053142A1 (en) * | 2021-09-30 | 2023-04-06 | National Centre For Cell Science | Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2265695A (en) * | 1995-01-17 | 1996-08-07 | Pfizer Inc. | The use of sertraline to treat cancer patients |
| US5958934A (en) * | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| FR2810677B1 (en) * | 2000-06-27 | 2004-10-01 | Urogene | PROCESS FOR IN VITRO DIAGNOSIS OF PROSTATE CANCER AND IMPLEMENTATION KIT |
| US6444477B1 (en) * | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
| IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
-
2002
- 2002-12-26 FR FR0216699A patent/FR2849382A1/en not_active Withdrawn
-
2003
- 2003-12-23 WO PCT/FR2003/003875 patent/WO2004060390A2/en not_active Ceased
- 2003-12-23 WO PCT/FR2003/003878 patent/WO2004061408A2/en not_active Ceased
- 2003-12-23 AU AU2003299399A patent/AU2003299399A1/en not_active Abandoned
- 2003-12-23 AU AU2003303568A patent/AU2003303568A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004061408A2 (en) | 2004-07-22 |
| FR2849382A1 (en) | 2004-07-02 |
| AU2003299399A8 (en) | 2004-07-29 |
| WO2004061408A3 (en) | 2004-08-19 |
| WO2004060390A3 (en) | 2004-08-19 |
| AU2003303568A1 (en) | 2004-07-29 |
| AU2003303568A8 (en) | 2004-07-29 |
| WO2004060390A2 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AUPS054702A0 (en) | Cancer therapy | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| AU2003224654A1 (en) | Photodynamic therapy for pre-melanomas | |
| AU2003266949A1 (en) | Compounds | |
| AU2003221098A1 (en) | Oligofluorenylene compounds | |
| AU2003224076A1 (en) | Antibody combination useful for tumor therapy | |
| AU2003272069A1 (en) | Novel floating dosage form | |
| AU2003212634A1 (en) | Compounds useful in the treatment of cancer | |
| AU2003256655A1 (en) | Therapeutic compounds for treating dyslipidemic conditions | |
| AU2003247005A1 (en) | Therapy combination | |
| AU2003222449A1 (en) | Medicine for treating cancer | |
| AU2003245794A1 (en) | Glycosaminoglycan-dnase combination therapy | |
| AU2003215150A1 (en) | Therapeutic compounds | |
| AU2003223538A1 (en) | Methods for the treatment of cancer | |
| AU2003244080A1 (en) | Phosphodiesterase inhibitor | |
| AU2003256323A1 (en) | Sos1 inhibitors | |
| AU2003257840A1 (en) | Transformer | |
| AU2003296545A1 (en) | Use of a trpm8-activating substance for the treatment of tumours | |
| AU2003299399A1 (en) | Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer | |
| AU2003296242A1 (en) | Thia-epothilone derivatives for the treatment of cancer | |
| AU2003283339A1 (en) | Cancer therapy determination | |
| AU2003260509A1 (en) | Acetylene compounds | |
| AU2003201729A1 (en) | Transformer | |
| AU2003232606A1 (en) | Surface reactor | |
| GB0208392D0 (en) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |